Platelet-activating factor(PAF) is a phospholipid-derived mediator which has been implicated in cutaneous inflammation, thus antagonists of PAF could form the basis of novel antiinflammatory treatments. My previous studies have demonstrated that keratinocytes both synthesize and express functional receptors for PAF. This project tests the hypothesis that PAF has proinflammatory effects on keratinocytes through two separate lines of investigation which will be conducted concurrently. First, an in vivo murine model system will be developed to evaluate: 1) the epicutaneous effects of specific PAF receptor (PAF-R) agonists and antagonists; 2) the potential antiinflammatory effects of potent PAF-R antagonists on experimentally-induced dermatitis. Second, an in vitro model system of the PAF-R will be developed through retroviral-mediated gene transfer of both the wild-type and truncated mutant PAF-R (which does not undergo homologous desensitization) into the PAF-R-negative epidermoid cell line KB. This PAF-R model system will allow characterization of the morphological and functional effects of the PAF-R in epidermal cells. These two separate lines of investigation will provide both information as well as tools for future studies to dissects the role of PAR in the complex cytokine network found in the skin, information which could be translated into novel therapeutic strategies.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Moshell, Alan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
Schools of Medicine
United States
Zip Code
Zhang, Qiwei; Southall, Michael D; Mezsick, Steven M et al. (2005) Epidermal peroxisome proliferator-activated receptor gamma as a target for ultraviolet B radiation. J Biol Chem 280:73-9
Marathe, Gopal K; Johnson, Christopher; Billings, Steven D et al. (2005) Ultraviolet B radiation generates platelet-activating factor-like phospholipids underlying cutaneous damage. J Biol Chem 280:35448-57
Zhang, Qiwei; Mousdicas, Nico; Yi, Qiaofang et al. (2005) Staphylococcal lipoteichoic acid inhibits delayed-type hypersensitivity reactions via the platelet-activating factor receptor. J Clin Invest 115:2855-61
Darst, Marc; Al-Hassani, Mohammed; Li, Tao et al. (2004) Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line. J Immunol 172:6330-5
Billings, Steven D; Southall, Michael D; Li, Tao et al. (2003) Amphiregulin overexpression results in rapidly growing keratinocytic tumors: an in vivo xenograft model of keratoacanthoma. Am J Pathol 163:2451-8
Li, Tao; Southall, Michael D; Yi, Qiaofang et al. (2003) The epidermal platelet-activating factor receptor augments chemotherapy-induced apoptosis in human carcinoma cell lines. J Biol Chem 278:16614-21
Southall, Michael D; Li, Tao; Gharibova, Lera S et al. (2003) Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J Pharmacol Exp Ther 304:217-22
Travers, Jeffrey B; Leung, Donald Y M; Johnson, Christopher et al. (2003) Augmentation of staphylococcal alpha-toxin signaling by the epidermal platelet-activating factor receptor. J Invest Dermatol 120:789-94
Petersen, Jeffrey E; Hiran, Tejindervir S; Goebel, W Scott et al. (2002) Enhanced cutaneous inflammatory reactions to Aspergillus fumigatus in a murine model of chronic granulomatous disease. J Invest Dermatol 118:424-9
Marques, Mariangela; Pei, Yong; Southall, Michael D et al. (2002) Identification of platelet-activating factor acetylhydrolase II in human skin. J Invest Dermatol 119:913-9

Showing the most recent 10 out of 24 publications